Skip to main content
. 2022 Jan 18;6:4. doi: 10.1038/s41698-021-00243-7

Fig. 5. Outperformance of the inter-model in squamous NSCLC.

Fig. 5

A, B The single mutations (A) and interaction effects of co-mutations (B) selected for model development. C Calibration curves of the three-models in the training sets-1/2. D Youden’s index based on the receiver operating characteristic curve of the three inter-scores and response to anti-PD-(L)1 monotherapy in the training sets-1/2. E Summary of the performances of the three models in all training/validation sets. F–H Comparison between the uni-model and the inter-model when two results are inconsistent (F). KM curves illustrating PFS on ICI treatment (G) and PFS benefit from ICI therapy over docetaxel (H). I–K Comparison between the null-inter-model and the inter-model when two results are inconsistent (I). KM curves illustrating PFS on ICI treatment (J) and PFS benefit from ICI therapy over docetaxel (K). L–N Association of the inter-score with blood TMB (L), tissue TMB (M), and neoantigen load (N). O Effectiveness of the inter-score in patients with different clinicopathological features, TMB, and PD-L1. Abbreviations: ICI immune checkpoint inhibitor, KM Kaplan-Meier, NSCLC nonsmall cell lung cancer, OS overall survival, PD-1 programmed death-1, PD-L1 programmed death-ligand 1, PFS progression-free survival, TMB tumor mutational burden.